Amanote Research

Amanote Research

    RegisterSign In

Targeting mTOR for the Treatment of AML. New Agents and New Directions.

Oncotarget - United States
doi 10.18632/oncotarget.290
Full Text
Open PDF
Abstract

Available in full text

Categories
Oncology
Date

June 4, 2011

Authors
Jessica K. AltmanAntonella SassanoLeonidas C. Platanias
Publisher

Impact Journals, LLC


Related search

Targeting Leukemia Stem Cell-Niche Dynamics: A New Challenge in AML Treatment

Journal of Oncology
Oncology
2019English

Targeting GIRK Channels for the Development of New Therapeutic Agents

Frontiers in Pharmacology
Pharmacology
2011English

New Directions and New Partnerships

1995English

New Directions for AAAS

Science
MultidisciplinaryPhilosophy of ScienceHistory
1977English

Targeting CGRP: A New Era for Migraine Treatment

CNS Drugs
PsychiatryMental HealthNeurologyPharmacology
2015English

New Directions for Nurses

American Journal of Public Health
EnvironmentalPublic HealthOccupational Health
1971English

New Directions for ILWCH

International Labor and Working-Class History
Organizational BehaviorHuman Resource ManagementHistory
1985English

New Directions for ACE

Journal of Applied Communications
1990English

Targeting the Mammalian Target of Rapamycin (mTOR): A New Approach to Treating Cancer

British Journal of Cancer
Cancer ResearchOncology
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy